MA45124A - Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients - Google Patents
Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patientsInfo
- Publication number
- MA45124A MA45124A MA045124A MA45124A MA45124A MA 45124 A MA45124 A MA 45124A MA 045124 A MA045124 A MA 045124A MA 45124 A MA45124 A MA 45124A MA 45124 A MA45124 A MA 45124A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- antibody
- biomarker
- level
- sample
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un procédé d'identification d'un sujet souffrant d'une leucémie lymphocytaire chronique (llc), d'un lymphome non hodgkinien (lnh), d'un lymphome à petits lymphocytes (lpl) ou d'une leucémie lymphoblastique aiguë (lla) qui est sensible à un traitement avec un anticorps anti-cd19, ledit procédé comprenant : a) la fourniture d'un échantillon de sang obtenu à partir dudit sujet avant le traitement avec ledit anticorps anti-cd19, b) la détermination du taux d'au moins un biomarqueur dans ledit échantillon choisi dans le groupe constitué de : i) le nombre de cellules nk périphériques, et ii) les taux d'expression de cd16 sur les cellules nk périphériques, c) la comparaison du taux dudit au moins un biomarqueur dans ledit échantillon à un niveau de coupure prédéterminé, les taux dudit au moins un biomarqueur égaux ou supérieurs au niveau de coupure prédéterminé étant indicatifs d'un sujet qui bénéficierait d'un traitement avec un anticorps anti-cd19. La présente invention concerne en outre un procédé de sélection d'un patient pour le traitement selon l'invention et l'utilisation d'un anticorps anti-cd19 pour le traitement d'un tel patient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16171885 | 2016-05-30 | ||
| PCT/EP2017/063045 WO2017207574A1 (fr) | 2016-05-30 | 2017-05-30 | Procédés de prédiction de bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45124A true MA45124A (fr) | 2017-12-07 |
| MA45124B1 MA45124B1 (fr) | 2021-05-31 |
Family
ID=56116221
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA57021A MA57021B1 (fr) | 2016-05-30 | 2017-05-30 | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
| MA45124A MA45124B1 (fr) | 2016-05-30 | 2017-05-30 | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA57021A MA57021B1 (fr) | 2016-05-30 | 2017-05-30 | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20190195879A1 (fr) |
| EP (2) | EP3916392B1 (fr) |
| JP (2) | JP7066639B2 (fr) |
| KR (1) | KR102416144B1 (fr) |
| CN (2) | CN109313194B (fr) |
| AU (1) | AU2017272608B2 (fr) |
| CY (1) | CY1124768T1 (fr) |
| DK (2) | DK3465214T3 (fr) |
| EA (1) | EA201892542A1 (fr) |
| ES (2) | ES2878156T3 (fr) |
| FI (1) | FI3916392T3 (fr) |
| HR (2) | HRP20240670T1 (fr) |
| HU (2) | HUE067450T2 (fr) |
| IL (1) | IL263103B2 (fr) |
| LT (2) | LT3916392T (fr) |
| MA (2) | MA57021B1 (fr) |
| MD (2) | MD3465214T2 (fr) |
| MX (2) | MX388502B (fr) |
| PL (2) | PL3465214T3 (fr) |
| PT (2) | PT3465214T (fr) |
| RS (2) | RS65540B1 (fr) |
| SG (2) | SG11201810159TA (fr) |
| SI (2) | SI3465214T1 (fr) |
| SM (2) | SMT202100291T1 (fr) |
| WO (1) | WO2017207574A1 (fr) |
| ZA (2) | ZA201808647B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3337506T1 (sl) | 2015-08-21 | 2021-12-31 | Morphosys Ag | Kombinacije in njihove uporabe |
| IL266216B2 (en) | 2016-10-28 | 2023-09-01 | Morphosys Ag | Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| JP2022532519A (ja) | 2019-05-03 | 2022-07-15 | モルフォシス・アーゲー | 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法 |
| AU2020375149A1 (en) * | 2019-10-31 | 2022-05-12 | Incyte Corporation | Sequential anti-CD19 therapy |
| JP7813225B2 (ja) * | 2019-10-31 | 2026-02-12 | インサイト・コーポレイション | 白血病またはリンパ腫の治療のためのレナリドミドと組み合わせた抗ｃｄ１９療法 |
| CA3181827A1 (fr) * | 2020-06-22 | 2021-12-30 | Morphosys Ag | Polytherapie antitumorale comprenant un anticorps anti-cd19 et des polypeptides bloquant le point de controle immunitaire inne sirp?-cd47 |
| CA3204063A1 (fr) * | 2020-12-04 | 2022-06-09 | Morphosys Ag | Polytherapie anti-cd19 |
| WO2026024668A1 (fr) * | 2024-07-22 | 2026-01-29 | Abbott Laboratories | Procédé de détermination d'un volume d'un liquide dans un échantillon |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101023367B1 (ko) | 1998-08-11 | 2011-03-18 | 바이오겐 아이덱 인크. | Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제 |
| EP1389203B8 (fr) | 2001-02-27 | 2010-03-10 | The Governement of the United States of America, represented by The Secretary Department of Health and Human services | Analogues de thalidomide utilises comme inhibiteurs de l'angiogenese |
| WO2005016326A2 (fr) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogues de la thalidomide utilises comme inhibiteurs potentiels de l'angiogenese |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| EP2216342B1 (fr) | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anticorps anti-CD19 |
| SI1853718T1 (sl) * | 2005-02-15 | 2016-02-29 | Duke University | Protitelesa anti-CD19 in uporabe v onkologiji |
| AU2006262232A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | CD19 antibodies and their uses |
| CA2635623C (fr) | 2005-12-30 | 2015-02-17 | Michael Super | Anticorps anti-cd19 d'immunogenicite reduite |
| JP5825756B2 (ja) | 2006-08-14 | 2015-12-02 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ１９を標的とする最適化抗体 |
| AU2007294575B2 (en) | 2006-09-08 | 2013-06-27 | Viela Bio, Inc. | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| ATE501436T1 (de) | 2006-09-13 | 2011-03-15 | Glycode | Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper |
| DK2176298T3 (en) | 2007-05-30 | 2018-02-12 | Xencor Inc | Methods and compositions for inhibiting CD32B-expressing cells |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| SG173654A1 (en) | 2009-02-23 | 2011-09-29 | Glenmark Pharmaceuticals Sa | Humanized antibodies that bind to cd19 and their uses |
| WO2011147834A1 (fr) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Anticorps contre cd19 et utilisations associées |
| EP2409993A1 (fr) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anticorps Anti-CD19 doté d'une fonction ADCC et d'un profil de glycosylation amélioré |
| EP2409712A1 (fr) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anticorps Anti-CD19 doté de fonctions ADCC et CDC et d'un profil de glycosylation amélioré |
| CA2817842A1 (fr) | 2010-11-15 | 2012-05-24 | Medimmune, Llc | Polytherapie pour lymphomes b |
| EP2524929A1 (fr) | 2011-05-17 | 2012-11-21 | Sanofi | Utilisation d'anticorps immunoconjugués anti-CD19 maytansinoïdes pour le traitement de symptômes de malignités CD19+lymphocytes B |
| EP2744515B1 (fr) | 2011-08-16 | 2022-02-09 | MorphoSys AG | Thérapie combinée d'un anticorps anti-cd19 avec un moutarde azotée |
| HRP20220224T1 (hr) * | 2011-08-16 | 2022-04-29 | Morphosys Ag | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom |
| EP2791165A4 (fr) * | 2011-12-12 | 2015-08-05 | Pikamab Inc | Prédiction de la sensibilité vis-à-vis d'une thérapie de maintenance par anticorps |
| CN106029098A (zh) * | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | 人源化rfb4抗cd22抗体 |
| AU2015277516A1 (en) * | 2014-06-16 | 2016-12-22 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (CLL) |
| JP6805137B2 (ja) | 2014-07-11 | 2020-12-23 | アンセルム（アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） | 血液学的癌を診断するための方法 |
-
2017
- 2017-05-30 SG SG11201810159TA patent/SG11201810159TA/en unknown
- 2017-05-30 HR HRP20240670TT patent/HRP20240670T1/hr unknown
- 2017-05-30 SM SM20210291T patent/SMT202100291T1/it unknown
- 2017-05-30 ES ES17728484T patent/ES2878156T3/es active Active
- 2017-05-30 MD MDE20190405T patent/MD3465214T2/ro unknown
- 2017-05-30 RS RS20240525A patent/RS65540B1/sr unknown
- 2017-05-30 FI FIEP21170716.1T patent/FI3916392T3/fi active
- 2017-05-30 SI SI201730823T patent/SI3465214T1/sl unknown
- 2017-05-30 MX MX2018014702A patent/MX388502B/es unknown
- 2017-05-30 AU AU2017272608A patent/AU2017272608B2/en active Active
- 2017-05-30 LT LTEP21170716.1T patent/LT3916392T/lt unknown
- 2017-05-30 PT PT177284841T patent/PT3465214T/pt unknown
- 2017-05-30 SI SI201731527T patent/SI3916392T1/sl unknown
- 2017-05-30 DK DK17728484.1T patent/DK3465214T3/da active
- 2017-05-30 JP JP2018562324A patent/JP7066639B2/ja active Active
- 2017-05-30 PL PL17728484T patent/PL3465214T3/pl unknown
- 2017-05-30 EA EA201892542A patent/EA201892542A1/ru unknown
- 2017-05-30 RS RS20210893A patent/RS62155B1/sr unknown
- 2017-05-30 SG SG10201911958SA patent/SG10201911958SA/en unknown
- 2017-05-30 PT PT211707161T patent/PT3916392T/pt unknown
- 2017-05-30 CN CN201780033793.9A patent/CN109313194B/zh active Active
- 2017-05-30 SM SM20240204T patent/SMT202400204T1/it unknown
- 2017-05-30 ES ES21170716T patent/ES2981046T3/es active Active
- 2017-05-30 US US16/305,482 patent/US20190195879A1/en not_active Abandoned
- 2017-05-30 WO PCT/EP2017/063045 patent/WO2017207574A1/fr not_active Ceased
- 2017-05-30 MA MA57021A patent/MA57021B1/fr unknown
- 2017-05-30 CN CN202211271570.5A patent/CN115932265A/zh active Pending
- 2017-05-30 MD MDE20220770T patent/MD3916392T2/ro unknown
- 2017-05-30 EP EP21170716.1A patent/EP3916392B1/fr active Active
- 2017-05-30 MA MA45124A patent/MA45124B1/fr unknown
- 2017-05-30 HR HRP20210938TT patent/HRP20210938T1/hr unknown
- 2017-05-30 LT LTEP17728484.1T patent/LT3465214T/lt unknown
- 2017-05-30 KR KR1020187038026A patent/KR102416144B1/ko active Active
- 2017-05-30 PL PL21170716.1T patent/PL3916392T3/pl unknown
- 2017-05-30 DK DK21170716.1T patent/DK3916392T3/da active
- 2017-05-30 HU HUE21170716A patent/HUE067450T2/hu unknown
- 2017-05-30 IL IL263103A patent/IL263103B2/en unknown
- 2017-05-30 HU HUE17728484A patent/HUE054860T2/hu unknown
- 2017-05-30 EP EP17728484.1A patent/EP3465214B1/fr active Active
-
2018
- 2018-11-28 MX MX2021014963A patent/MX2021014963A/es unknown
- 2018-12-20 ZA ZA2018/08647A patent/ZA201808647B/en unknown
-
2021
- 2021-01-15 ZA ZA2021/00296A patent/ZA202100296B/en unknown
- 2021-07-13 CY CY20211100629T patent/CY1124768T1/el unknown
-
2022
- 2022-04-27 JP JP2022072884A patent/JP7511806B2/ja active Active
- 2022-05-25 US US17/824,266 patent/US20220283166A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45124A (fr) | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients | |
| Benguigui et al. | Interferon-stimulated neutrophils as a predictor of immunotherapy response | |
| Varettoni et al. | Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms | |
| Holmgren et al. | Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. | |
| Palm et al. | The norepinephrine‐driven metastasis development of PC‐3 human prostate cancer cells in BALB/c nude mice is inhibited by β‐blockers | |
| Shon et al. | Severity of DSS-induced colitis is reduced in Ido1-deficient mice with down-regulation of TLR-MyD88-NF-kB transcriptional networks | |
| Strasser et al. | Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile | |
| Quartuccio et al. | The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study | |
| Borilova Linhartova et al. | Genetic determinants and postorthodontic external apical root resorption in Czech children | |
| Heidel et al. | The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML | |
| Lau et al. | Genetic association of ankylosing spondylitis with TBX21 influences T-bet and pro-inflammatory cytokine expression in humans and SKG mice as a model of spondyloarthritis | |
| Galatola et al. | Gene expression profile of peripheral blood monocytes: a step towards the molecular diagnosis of celiac disease? | |
| Shinohara et al. | A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction | |
| US20180111342A1 (en) | Kit for in vitro or ex vivo measurement of scd127 expression in a biological sample | |
| Akhter et al. | CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series | |
| Angelot‐Delettre et al. | Intracytoplasmic detection of TCL1—but not ILT7—by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis | |
| Wang et al. | Transcriptome analysis of gingival tissues of enamel‐renal syndrome | |
| Isidro-Hernández et al. | Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice | |
| Dehmel et al. | Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long‐term renal allograft outcome | |
| Hannula-Jouppi et al. | Genetic susceptibility to non-necrotizing erysipelas/cellulitis | |
| Zhang et al. | Genomewide association studies for hematological traits and T lymphocyte subpopulations in a Duroc× Erhualian F2 resource population | |
| Hartling et al. | Gene variation in IL-7 receptor (IL-7R) α affects IL-7R response in CD4+ T cells in HIV-infected individuals | |
| HK1211042A1 (en) | Inflammation-enabling polypeptides and uses thereof | |
| Li et al. | Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcμR) in patients with chronic lymphocytic leukemia | |
| Yamauchi et al. | Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma |